Shield Therapeutics PLC Notice of Results (4004H)
July 31 2019 - 8:21AM
UK Regulatory
TIDMSTX
RNS Number : 4004H
Shield Therapeutics PLC
31 July 2019
Shield Therapeutics plc
("Shield" or the "Group")
Notice of results
London, UK, 31 July 2019: Shield Therapeutics plc (LSE: STX), a
commercial stage, pharmaceutical company with a focus on addressing
iron deficiency, announces it will release its interim results for
the six months ended 30 June on Wednesday 7 August 2019.
Analyst briefing
A briefing for analysts will take place at 9.30am on Wednesday 7
August 2019. If you would like to register, please contact Walbrook
PR on 020 7933 8780 or email shield@walbrookpr.com
For further information please contact:
Shield Therapeutics plc www.shieldtherapeutics.com
Carl Sterritt, Chief Executive
Officer +44 (0)20 7186 8500
Tim Watts, Chief Financial
Officer
Nominated Advisor and Broker
Peel Hunt LLP
James Steel/Dr Christopher
Golden +44 (0)20 7418 8900
Joint Broker
finnCap Ltd
Geoff Nash/Matt Radley/Alice
Lane +44 (0)20 7220 0500
Financial PR & IR Advisor
Walbrook PR +44 (0)20 7933 8780 or shield@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7584 391
Paul McManus / Lianne Cawthorne 303
About Shield Therapeutics plc
Shield is a de-risked, commercial stage, specialty
pharmaceutical company delivering innovative pharmaceuticals to
address patients' unmet medical needs. The Company's clear purpose
is to help its patients become people again, by enabling them to
enjoy the things that make the difference in their everyday lives.
The Group has a marketed product, Feraccru(R) / Accrufer(R), for
the treatment of iron deficiency in adults which has exclusive IP
rights until the mid-2030s. Feraccru(R) / Accrufer(R), is approved
by the FDA, EMA and Swiss Medic for the treatment of iron
deficiency in adults and is commercialised in the European Union by
Norgine BV, with a US commercialisation partner currently being
selected. For more information please visit
www.shieldtherapeutics.com.
About Feraccru(R)/ Accrufer(R)
Feraccru(R)/ Accrufer(R) is a novel, stable, non-salt based oral
treatment for adults with iron deficiency with or that has been
shown to be an efficacious and well-tolerated therapy in a range of
controlled phase 3 trials. Following the recently announced
positive results of the Phase IIIb AEGIS-H2H study in which
Feraccru(R) demonstrated it was non-inferior to
intravenously-administered Ferinject(R) at delivering improvements
in haemoglobin levels without requiring hospital-based
administration, Feraccru(R)/ Accrufer(R) offers a compelling
alternative to IV Iron for those patients that cannot tolerate
salt-based oral iron therapies and wish to avoid the complexities
of infusion-based therapies.
When salt-based oral iron therapies are ingested they can cause
a range of mild-to-severe gastrointestinal tract (GI) adverse
events, including nausea, bloating and constipation. These lead to
poor tolerability, reduced patient compliance and ultimately
treatment failure. Feraccru(R)/ Accrufer(R) is not an iron salt;
iron can be absorbed from the ferric maltol molecule and, as a
result, it does not routinely cause the same treatment-limiting
intolerance issues.
Prior to Feraccru(R)/ Accrufer(R), IV iron therapies were the
only realistic alternative treatment option for patients intolerant
of or unwilling to take salt-based oral iron therapies. However,
use of such an invasive, costly, inconvenient and complex to
administer treatment option, which is associated with potentially
life-threatening and spontaneous hypersensitivity reactions, means
there remains a clear unmet medical need for patients with iron
deficiency to have access to an effective therapy like Feraccru(R)/
Accrufer(R) that is well tolerated, convenient and does not require
hospital-based administration.
About Iron Deficiency
The WHO state that iron deficiency is the most common and
widespread nutritional disorder in the world. As well as affecting
a large number of children and women in non-industrialized
countries, it is the only nutrient deficiency which is also
significantly prevalent in virtually all industrialized nations.
There are no current global figures for iron deficiency, but using
anaemia as an indirect indicator it can be estimated that most
preschool children and pregnant women in non-industrialized
countries, and at least 30-40% in industrialized countries, are
iron deficient.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORBBGDRGDXBGCB
(END) Dow Jones Newswires
July 31, 2019 08:21 ET (12:21 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2023 to Apr 2024